Crispr Therapeutics Ag · NASDAQ:CRSP
Crispr Therapeutics — Investor Day (June 2022)
6 slides from Crispr Therapeutics's investor day presentation, Jun 21, 2022
Slide 1: CRISPR Therapeutics Innovation Day
CRISPR Therapeutics Innovation Day June 21, 2022 Exhibit 99.1
Slide 2: Forward-looking statements
The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) its plans
Slide 3: Path Forward for BCMA-Directed CAR-T
Path Forward for BCMA-Directed CAR-T Completed CTX120 dose escalation up to Dose Level (DL) 4; 1 subject treated at DL5 Further data disclosure in a future scientific publication Pivot to next-generation allogeneic CAR-T program for multiple myeloma (CTX121) No dose limiting toxicities (DLT) observe
Slide 4: Patient Baseline Characteristics and Safety in COBALT-RCC
Patient Baseline Characteristics and Safety in COBALT-RCC Acceptable safety profile across all dose levels to date, including no DLTs No instances of tumor lysis syndrome, infusion reactions, HLH, ICANS, GvHD or secondary malignancies occurred 7 (50%) patients had Gr 1-2 CRS; no Gr ≥ 3 CRS events 3
Slide 5: Evidence of Activity for CTX130 in RCC – a First for Allogeneic Cell Therapy in Solid Tumors
Evidence of Activity for CTX130 in RCC – a First for Allogeneic Cell Therapy in Solid Tumors CTX130 shows promising potential disease control in COBALT-RCC Cell dose (CAR+ T cells) DL1 3x107 N=3 DL2 1x108 N=3 DL3 3x108 N=4 DL4 9x108 N=4 Total N=14 Overall response rate 1 (33) 0 0 0 1 (7) Stable dise
Slide 6: Case Study | Durable Complete Response in RCC with CTX130
Case Study | Durable Complete Response in RCC with CTX130 Subject Overview Patient profile 64-year-old male with clear cell RCC diagnosed in 2017 1 prior line of therapy with cabozantinib and atezolizumab Relapsed after PR with lesions in the lung and pleura CD70+ expression: 100% at baseline Effica